MediWound Ltd. Stock News

MediWound (MDWD) delivered earnings and revenue surprises of 0.00% and -15.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Submitted Biological License Application to the FDA for NexoBrid  EscharEx U.S. Phase 2 Study Resumed Patient ScreeningYAVNE, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD)

The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wou

MediWound (MDWD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced it has submitted a

Zacks.com featured highlights include: MediWound, Issuer Direct, BWX Technologies and Teekay Tankers

Investors always look for companies with a high level of profitability regardless of the present market condition.

MediWound (MDWD) delivered earnings and revenue surprises of 35.71% and 4.42%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of MediWound (NASDAQ:MDWD) moved higher by 6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 40.00% over the past year to ($0.09), which b

YAVNE, Israel, May 20, 2020 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs.